-
1 Comment
Jiangsu Nhwa Pharmaceutical Co., LTD is currently in a long term downtrend where the price is trading 4.3% below its 200 day moving average.
From a valuation standpoint, the stock is 53.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Jiangsu Nhwa Pharmaceutical Co., LTD's total revenue rose by 3.7% to $987M since the same quarter in the previous year.
Its net income has increased by 10.4% to $157M since the same quarter in the previous year.
Finally, its free cash flow grew by 278.5% to $532M since the same quarter in the previous year.
Based on the above factors, Jiangsu Nhwa Pharmaceutical Co., LTD gets an overall score of 4/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100000CG8 |
| Sector | Healthcare |
| Dividend Yield | 1.7% |
|---|---|
| Market Cap | 22B |
| PE Ratio | 18.44 |
| Target Price | 29.7425 |
| Beta | -0.1 |
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It's product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company's products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002262.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
